73907-93-4

Usage

Chemical Class

Indazoles

Derivative of

Indazole-6-carboxylic acid

Structural Relation

Indacaterol (clinically approved drug for chronic obstructive pulmonary disease)

Potential Use

Pharmacological tool for studying indazoles and their biological activities

Additional Information

Further research needed to understand its pharmacological properties and potential uses.

Upstream product

• 302-17-0 chloral hydrate 
• 6967-12-0 6-amino-1H-indazole 

Downstream Products

• 73907-94-5 pyrrolo<2,3-g>indazole-7,8-dione 
• 75844-39-2 6-amino-7-methoxycarbonyl-1-methylindazol 
• 73907-98-9 6-amino-1H-indazole-7-carboxylic acid methyl ester 
• 73907-95-6 6-aminoindazole-7-carboxylic acid 
• 73907-90-1 prox-benzoisoallopurinol 
• 73907-99-0 ethyl 6-aminoindazole-7-carboxylate 
• 73907-96-7 6-(β-benzoylthioureido)indazole-7-carboxylic acid 

Relevant academic research and scientific papers

Synthesis of prox-Benzoisoallopurinol

Pyrazoloquinazolin-9-one (prox-benzoisoallopurinol, 1), an extented analogue of 7-hydroxypyrazolopyrimidine (isoallopurinol, 2) and a potential dimensional probe for substrates of xanthine oxidase, has been synthesized by two independent routes.The title compound, prepared by elaboration of either a suitably substituted indazole or a quinazolinone, was found to be an active substrate for and an alternative-substrate inhibitor of xanthine oxidase.The product of enzymatic oxidation of prox-benzoisoallopurinol has been identified as the corresponding prox-benzoisoalloxanthine.

Quinazoline derivatives

Novel quinazoline derivatives of the formula (1) STR1 wherein ring C is a pyrazole ring fused to ring B in two vicinal positions thereof that are not fused with ring A. The novel formula (1) compounds or pyrazolo-quinazoline-ones are structurally related to allopurinol, a well known drug useful in the treatment of gout and are expected to replace or complement allopurinol in the therapeutic use thereof. The generic name Benzoallopurinol is suggested for the novel formula (1) compounds; formula (1) includes angular and linear structures of the interfused rings A, B and C. Two methods for producing the novel formula (1) compounds are disclosed. The first method starts from the indazole structure that includes the interfused rings B and C, and ring A is formed on the indazole moiety. The second method starts from the quinazoline structure that includes interfused rings A and B, and the pyrazole ring C is formed on the benzo moiety (ring B) of the quinazoline structure. Either method may lead to angular or linear benzoallopurinols depending upon the substituents introduced into the starting structure for forming the complemental ring thereon.